Is the CRP-Albumin-Lymphocyte (CALLY) Index Effective in Predicting Postoperative Delirium in Geriatric Patients Undergoing Hip Fracture Surgery

Launched by ANKARA ATATURK SANATORIUM TRAINING AND RESEARCH HOSPITAL · Feb 7, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to predict the risk of postoperative delirium (POD) in older patients who are having surgery for hip fractures. POD is a serious condition that can cause confusion and changes in behavior after surgery, and it can lead to longer hospital stays and other health complications. The researchers are looking at a combination of three blood markers—C-reactive protein (CRP), albumin, and lymphocyte count—to create a new index called the CALLY Index. They want to see if this index can help identify patients at higher risk for developing POD, which could improve care and outcomes after surgery.

To be eligible for the study, participants must be 65 years or older and scheduled for surgery on a specific type of hip fracture. However, those with certain conditions, like pre-existing dementia, severe weight issues, or other serious health problems, won’t be included. Participants in the trial will have various health data collected before and after their surgery, and they will be monitored for signs of delirium for three days following their procedure. This study aims to improve our understanding of POD and potentially help doctors better predict and manage this condition in elderly patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 65 years and older who undergo surgery for femoral neck or intertrochanteric fractures
• Exclusion Criteria:
• • Patients with preoperative delirium
• • Patients with preoperative dementia
• • Patients with pathological fractures
• • Patients with open fractures
• • Patients with systemic or localized infections in the fracture region during the preoperative period
• • Patients with multiple trauma
• • Patients with a BMI \<18.5 or ≥35
• • Patients with chronic organ failure
• • Patients with advanced-stage cancer